
Contents

| | | |
|----------|--|----|
| 1 | The Aqueous Interface of a Soluble Protein or the Birth of Epistuctural Biology | 1 |
| 1.1 | The Aqueous Interface as Determined by the Structure of a Soluble Protein | 2 |
| 1.2 | Protein Dehydrons Generate Interfacial Tension: Breakdown of the Conventional Dielectric Theory at Nanoscales | 6 |
| 1.3 | The Aqueous Interface from a Structure-Centric Perspective: Many-Body Problem for the Drug Designer | 10 |
| 1.4 | Dehydrons Promote Protein Associations: A Structural Perspective | 13 |
| 1.5 | Dehydron Stickiness: Epistuctural View of Biomolecular Interfaces | 16 |
| 1.6 | Biomolecular Interfaces and Drug-Target Associations: A Glimpse at New Possibilities for Molecular Engineering | 19 |
| 1.7 | Biomolecular Interfaces Constrain the Architecture of Soluble Proteins | 21 |
| | Problems | 30 |
| | References | 31 |
| 2 | Electrostatic Exploration of Biomolecular Interfaces: The Chemical Function of Interfacial Water | 35 |
| 2.1 | Interfacial Tension and Non-Debye Polarization of Interfacial Water | 35 |
| 2.2 | Non-Debye Polarization of the Aqueous Interface of a Soluble Protein | 39 |
| 2.3 | Chemical Functionality of the Aqueous Interface: A Consequence of the Breakdown of Debye's Dielectric Picture | 42 |
| 2.4 | A New Twist on Enzyme Catalysis: Nanoscale Packing Defects as Catalytic Stimulators | 48 |
| | Problems | 50 |
| | References | 51 |

| | | |
|----------|--|-----|
| 3 | Semiempirical Solution to the Protein Folding Problem Through a Combination of Structural and Epistrial Approaches. | 53 |
| 3.1 | Structure-Centric Approach to Protein Folding: Cooperativity and Wrapping Delineate a Many-Body Problem. | 54 |
| 3.2 | Hydrogen-Bond Wrapping Requires Cooperative Folding | 56 |
| 3.3 | Generating Cooperative Folding Trajectories | 58 |
| 3.4 | Wrapping Patterns Along Folding Pathways | 62 |
| 3.5 | Nanoscale Dielectric Theory of Folding Cooperativity: The Conventional “Effective Permittivity” Approach | 67 |
| 3.6 | The Dehydronic Field Commits the Chain to Fold | 71 |
| 3.7 | The Biomolecular Interface in Protein Folding: The Principle of Minimal Epistrial Distortion | 72 |
| 3.8 | What Did It Take to Solve the Protein Folding Problem? | 78 |
| | Problems | 79 |
| | References | 81 |
| 4 | Packing Defects and Protein Hydration: Dynamics of the Aqueous Interface | 83 |
| 4.1 | Dynamic Singularities of Biomolecular Interfaces | 83 |
| 4.2 | Impact of Protein Packing Defects on Interfacial Dynamics | 84 |
| 4.3 | Dehydrons Loosen up the Aqueous Interface | 86 |
| 4.4 | Displacing Loose Hydrating Molecules: A Blueprint for the Drug Designer | 90 |
| 4.5 | How Do Dehydrons Steer Interfacial Water? | 92 |
| | Problems | 93 |
| | References | 95 |
| 5 | Proteins in the Order–Disorder Twilight: Unstable Interfaces Promote Protein Aggregation | 97 |
| 5.1 | Dehydron Clusters and Disordered Regions | 97 |
| 5.2 | Semiclassical View of Discrete Dielectrics Around Dehydrons | 99 |
| 5.3 | Semiclassical Treatment of Dielectric Modulation of Interfacial Water Around Dehydrons | 102 |
| 5.4 | Dielectric Quenching in the p53 DNA-Binding Domain: A Study Case | 106 |
| 5.5 | Proteins with Dehydron Clusters: Structural View of the Order–Disorder Twilight | 108 |

| | | |
|----------|--|------------|
| 5.6 | Inferring Dehydrons from Protein Sequence: Water-Exposed Backbone and Disorder Propensity | 111 |
| 5.7 | Misfolding and Aggregation: Massive Violation of Architectural Constraints for Protein Structure | 115 |
| | Problems | 120 |
| | References | 124 |
| 6 | Evolution of Protein Structure Degradation and Lessons for the Drug Designer | 127 |
| 6.1 | An Evolutionary Context for the Drug Designer | 127 |
| 6.2 | Comparing Protein Wrapping Across Species: Hallmarks of Nonadaptive Traits | 129 |
| 6.3 | Wrapping and Natural Selection | 129 |
| 6.4 | How Do Humans Cope with Inefficient Selection? | 132 |
| 6.4.1 | Regulatory Patterns Segregating Paralog Proteins | 133 |
| 6.4.2 | Wrapping Deficiency Causes Dosage Imbalance Causes Regulation Dissimilarity | 136 |
| 6.5 | Human Capacitance to Cope with Dosage Imbalances in Under-Wrapped Proteins | 142 |
| 6.6 | Fitness Catastrophes for the Human Species Arising from Nature's "Evolutionary Gambit" to Promote Interactome Complexity | 143 |
| 6.7 | Why Should the Drug Designer Be Mindful of Molecular Evolution? | 145 |
| 6.8 | Some Consequences for Evolutionary Technology | 147 |
| | Problem | 148 |
| | References | 148 |
| 7 | Chemical Functionality of the Aqueous Interface in Soluble Proteins | 151 |
| 7.1 | Dehydrons Induce Chemical Basicity in the Aqueous Interface | 151 |
| 7.2 | Exploring the Chemical Functionality of Dehydrons in Specific Proteins | 156 |
| 7.3 | The Dehydrone as a Two-Step Catalytic Engine | 161 |
| 7.4 | Quantum Mechanical Exploration of Chemical Events Involving Dehydrons | 161 |
| 7.5 | Methodology for Quantum Mechanical Assessment of the Chemical Role of Dehydrons | 163 |
| 7.6 | Capturing Chemical Events Involving Dehydrons | 165 |
| | Problem | 172 |
| | References | 172 |

| | | |
|-----------|--|------------|
| 8 | The Biomolecular Interface as a Selectivity Filter for Drug-Based Targeted Therapy | 175 |
| 8.1 | The Control of Drug Specificity: An Imperative for Drug Design | 176 |
| 8.2 | Epiststructural Drug Design: Ligands Wrap Protein Packing Defects upon Binding to the Target Protein | 180 |
| 8.3 | Poor Dehydron Wrappers Make Poor Drugs Even at High Affinity: The <i>Staurosporine</i> Lesson. | 182 |
| 8.4 | The Biomolecular Interface as a Selectivity Filter | 183 |
| 8.5 | Epiststructure-Based Drug Design | 184 |
| 8.6 | Wrapping-Based Selectivity | 187 |
| 8.7 | Targeting Dehydrons is an Effective Strategy for Selectively Blocking Protein Functions | 189 |
| 8.8 | Advantages and Shortcomings in Targeting Activation-Loop Dehydrons | 190 |
| | Problem | 190 |
| | References. | 191 |
| 9 | Wrapping-Based Re-engineering of an Anticancer Drug to Make it Safer | 193 |
| 9.1 | Building a Safer <i>Imatinib</i> | 193 |
| 9.2 | Unique Dynamic Singularities in the Aqueous Interface of the Target Protein Provide the Blueprint for Imatinib Redesign | 194 |
| 9.3 | <i>In Silico</i> Assays of the Efficacy of a Wrapping Drug to Displace Labile Interfacial Water. | 197 |
| 9.4 | High-Throughput Screening: Test Tube Validation of the Engineered Specificity | 197 |
| 9.5 | In Vitro Assays: Selectively Modulating the Impact of Imatinib. | 202 |
| 9.6 | In Vitro Assay of the Selective Anticancer Activity of the Wrapping Design. | 206 |
| 9.7 | Enhanced Safety of the Wrapping-Based Imatinib Redesign in Animal Models of Gastrointestinal Stromal Tumor. | 209 |
| 9.8 | Controlled Specificity Through Rational Design | 212 |
| | Problems. | 212 |
| | References. | 214 |
| 10 | Biomolecular Interfaces Provide Universal Markers for Drug Specificity and Personalized Medicine | 217 |
| 10.1 | Universal Selectivity Filter for Rationally Designed Kinase Inhibitors: An Imperative for Drug Safety and Personalized Medicine. | 218 |

| | | |
|-----------|---|------------|
| 10.2 | A Computational Tool Box for Comparative Analysis of Biomolecular Interfaces Across the Human Kinome | 219 |
| 10.2.1 | Dehydron Inference for Proteins with Unreported Structure | 219 |
| 10.2.2 | Alignment of Targetable Regions in the Biomolecular Interface Across the Human Kinome | 220 |
| 10.3 | Is the Biomolecular Interface Pharmacologically Relevant?. . . | 221 |
| 10.4 | Wrapping-Based Target Library for the Human Kinome: Broadening the Technological Base of Drug Discovery | 226 |
| 10.5 | Annotations in a Library of Specificity-Promoting Target Features | 228 |
| 10.6 | Kinome-Wide Dehydron Library as a Biotechnological Resource. | 233 |
| 10.7 | Wrapping Specificity for Personalized Molecular Medicine | 233 |
| | Problem | 239 |
| | References. | 240 |
| 11 | Controlling Induced Folding Through Wrapping Drug Design . . . | 243 |
| 11.1 | Induced Folding: The <i>Bête Noire</i> of Drug Design | 244 |
| 11.2 | Wrapping the Floppy Target: A Tractable Case of Induced Folding | 244 |
| 11.3 | Crating Floppy Regions in Drug Targets | 247 |
| 11.4 | Steering Induced Folding: A Dynamic Selectivity Filter. | 251 |
| 11.5 | WBZ_4: First JNK Inhibitor Designed Using Dynamic Information. | 252 |
| 11.6 | Induced Disruption of Preformed Dehydrons: A Design Strategy Based on Boosting Entropy? | 253 |
| | Problems. | 254 |
| | References. | 257 |
| 12 | Wrapping Drug Combinations for Therapeutic Editing of Side Effects: Systems Biology Meets Wrapping Technology. | 259 |
| 12.1 | The Editor Concept in Multicomponent Drug Therapy. | 259 |
| 12.2 | Editing Out Pernicious Side Effects Through Combination Drug Therapy | 260 |
| 12.3 | Designing a Therapeutic Editor Using the Wrapping Selectivity Filter | 265 |
| 12.4 | Therapeutic Editing: Toward a Proof of Principle | 267 |
| 12.5 | Future Perspectives for the Editing Therapy | 270 |
| | Problem | 271 |
| | References. | 283 |

| | | |
|-----------|---|-----|
| 13 | Multitarget Control of Drug Impact: A Therapeutic Imperative in Cancer Systems Biology | 285 |
| 13.1 | Is Systems Biology Truly Advocating for Promiscuous Drugs in Anticancer Therapy? | 285 |
| 13.2 | Cleaning Dirty Drugs with the Dehydron Filter: Rationale | 288 |
| 13.3 | Cleaning Dirty Drugs with Dehydron Filters: The Proof of Concept | 290 |
| 13.4 | Taming <i>Staurosporine</i> Promiscuity Through the Dehydron Filter | 294 |
| 13.5 | Systems Biology Inspires Wrapping Designs of Multitarget Drugs | 297 |
| 13.6 | Taming Sunitinib Promiscuity to Enhance Safety and Therapeutic Efficacy | 303 |
| 13.7 | Controlled Promiscuity: A Paradigm Shift? | 304 |
| | Problem | 307 |
| | References. | 308 |
| 14 | Engineering Therapeutic Alignments Between Immune Response and Molecularly Targeted Cancer Treatment | 311 |
| 14.1 | Removal of Drug-Induced Immunosuppressive Effects in Anticancer Drug Therapy: An Imperative for the Pharmaceutical Industry | 311 |
| 14.2 | Therapeutic Shortcomings of Anticancer Drugs that Suppress the Adaptive Immune Response | 312 |
| | 14.2.1 Undesired Cross-Reactivity Modulating the Immune Response | 312 |
| | 14.2.2 Predictably Immunosuppressive Anticancer Drugs | 315 |
| 14.3 | Strategies to Redesign Anticancer Drugs and Turn Them Immunosynergic | 315 |
| 14.4 | Evaluation of Immunosynergic Drug Prototypes | 319 |
| 14.5 | Building Immunosynergies in the Context of HIV-1 Induced Immunosuppression. | 320 |
| | Problem | 321 |
| | References. | 321 |
| 15 | High-Level Quantum Chemistry Empowers the Wrapping Technology for Drug Design | 325 |
| 15.1 | Incorporating Quantum Mechanical Effects into Drug Design | 325 |
| 15.2 | Halogen Bond Synergizing with a Wrapping Interaction: A Novel Motif for Drug Design | 326 |
| | Problems. | 328 |
| | References. | 329 |

| | |
|---|-----|
| Epilogue: New Frontiers | 331 |
| Appendix 1: Code for Dehydron Identification | 335 |
| Appendix 2: Answers to Problems | 343 |
| Index | 367 |



<http://www.springer.com/978-3-319-16849-4>

Biomolecular Interfaces

Interactions, Functions and Drug Design

Fernandez Stigliano, A.

2015, XIX, 372 p. 145 illus., 86 illus. in color., Hardcover

ISBN: 978-3-319-16849-4